Gossamer Bio, Inc. (NASDAQ:GOSS) Stock Has Average Target Price of $256.00

Key Points

• Analyst views are mixed: Of 10 firms covering Gossamer Bio, five rate it a buy, three hold, and two sell, resulting in an average “Hold” recommendation. The reported average 1-year price target is $256.
• Shares have fallen sharply: GOSS opened at $9.77, compared with a 52-week range of $8.29 to $309.60; its 50-day and 200-day moving averages were $10.81 and $38.10, respectively.
• Institutional investors own 81.23% of the stock, and several firms increased or initiated positions in the second quarter. Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib for pulmonary hypertension.

Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) has been given an average recommendation of "Hold" by the ten research firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $256.00.

A number of equities analysts have issued reports on the company. Chardan Capital reiterated a "buy" rating on shares of Gossamer Bio in a research note on Monday, October 26th. Leerink Partners raised Gossamer Bio from a "market perform" rating to an "outperform" rating and set a $80.00 price objective for the company in a research note on Tuesday, July 28th. Weiss Ratings lowered Gossamer Bio from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday. Wall Street Zen cut Gossamer Bio from a "hold" rating to a "sell" rating in a research report on Sunday, September 20th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Gossamer Bio in a research report on Thursday, August 27th.

Institutional Trading of Gossamer Bio

Large investors have recently added to or reduced their stakes in the stock. Corient Private Wealth LP increased its stake in Gossamer Bio by 41.3% in the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company's stock worth $927,000 after purchasing an additional 1,647,315 shares during the period. Hsbc Holdings PLC lifted its position in Gossamer Bio by 1,289.4% in the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company's stock valued at $267,000 after purchasing an additional 1,469,175 shares during the last quarter. Bank of America Corp DE bought a new stake in Gossamer Bio in the second quarter valued at approximately $65,000. Hhlr Advisors LTD. purchased a new stake in shares of Gossamer Bio during the second quarter valued at approximately $819,000. Finally, ARCH Venture Management LLC purchased a new stake in shares of Gossamer Bio during the second quarter valued at approximately $1,326,004. Hedge funds and other institutional investors own 81.23% of the company's stock.

Gossamer Bio Stock Performance

GOSS opened at $9.77 on Monday. The company has a fifty day moving average price of $10.81 and a two-hundred day moving average price of $38.10. Gossamer Bio has a 1-year low of $8.29 and a 1-year high of $309.60. The company has a market cap of $59.69 million, a P/E ratio of -0.17 and a beta of 2.28.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.